A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon
(PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD).
Treatment was followed by 24 weeks of treatment-free follow-up.